

## Atrial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke

Status: Recruiting

### Eligibility Criteria

This study is NOT accepting healthy volunteers

### Conditions & Interventions

**Conditions:**

Stroke

**Keywords:**

Apixaban, Aspirin, Atrial Cardiopathy, Clinics and Surgery Center (CSC), Cryptogenic stroke, Ischemic stroke

### More Information

**Description:** ARCADIA is a multicenter, biomarker-driven, randomized, double-blind, active-control, phase 3 clinical trial of apixaban versus aspirin in patients who have evidence of atrial cardiopathy and a recent stroke of unknown cause. Eleven hundred subjects will be recruited over 2.5 years at 120 sites in the NINDS StrokeNet consortium. Subjects will be followed for a minimum of 1.5 years and a maximum of 4 years for the primary efficacy outcome of recurrent stroke and the primary safety outcomes of symptomatic intracranial hemorrhage and major hemorrhage other than intracranial hemorrhage.

**Contact(s):** Anna Brauch - brauc019@umn.edu

**Principal Investigator:** Benjamin Miller

**Phase:** Phase III

**IRB Number:** STUDY00001759

**System ID:** NCT03192215

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.